<DOC>
	<DOCNO>NCT01411709</DOCNO>
	<brief_summary>A pilot investigation stress relieve property Vitano® ass follow hypothesis Individuals expose Vitano® demonstrate diminish blood pressure heart rate response mental stress compare individual control condition Physiological recovery ( BP , HR cortisol ) mental stress enhance individual expose Vitano® compare individual control condition Vitano® positive effect cognitive functioning . Subjective rating stress reduce individual expose Vitano® compare individual control condition There significant improvement subjective well-being individual take Vitano® .</brief_summary>
	<brief_title>A Study On The Effect Of Vitano® On Physiological And Psychological Responses To Psychological Stress</brief_title>
	<detailed_description />
	<mesh_term>Stress , Psychological</mesh_term>
	<criteria>subject able read understand Informed Consent Form ( ICF ) , understand study procedure . The subject sign ICF . Healthy male female subject age 1835 year inclusive . Attempts make achieve equal gender ratio appropriate screening procedure , failure preclude analysis final data set . A score 30 Spielberger StateTrait Anxiety Inventory ( STAI ) . The subject agree use suitable method contraception study 3 month afterwards . The subject nonsmoker . The subject , opinion Investigator , healthy basis medical history , vital sign , result routine laboratory test . The subject pregnant breast feeding . The subject consumes 5 caffeinecontaining beverage per day . The subject colour blind . Clinically significant hepatic renal abnormality determine laboratory test . BMI 33 . History alcohol , narcotic , benzodiazepine , substance abuse dependence within 12 month precede Visit 1 . Positive alcohol breath test visit . A repeat test allow . [ NOTE : subject must tell avoid consumption alcoholic beverage least 24 hour prior attend Centre ] . Use medication may interfere study outcome and/or interfere IMP within 2 week 5 half life precede first treatment phase , exception contraceptive pill , nonsteroidal analgesic , paracetamol . [ NOTE : Concomitant medication influence study outcome and/or interfere IMP may allow discretion Investigator ] . Current participation another clinical trial investigational noninvestigational drug device , participation another clinical trial within 3 month precede Visit 1 ( screen visit ) . Any condition , Investigator 's opinion , compromise subject 's ability meet protocol requirement complete study . Moderate severe anxiety* *If participant find moderate severe anxiety screen process refer University Counselling service .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>